Cargando…
Anti-Drug Antibodies, Drug Levels, Interleukin-6 and Soluble TNF Receptors in Rheumatoid Arthritis Patients during the First 6 Months of Treatment with Adalimumab or Infliximab: A Descriptive Cohort Study
OBJECTIVES: With the present study we wanted to explore the impact of treatment with a tumor necrosis factor-α -inhibitor (TNFi) on levels of soluble biomarkers in rheumatoid arthritis (RA) patients and to identify predictors of impaired drug levels and development of anti-TNFi antibodies (anti-TNFi...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5016088/ https://www.ncbi.nlm.nih.gov/pubmed/27606615 http://dx.doi.org/10.1371/journal.pone.0162316 |
_version_ | 1782452538601111552 |
---|---|
author | Eng, Grith Petersen Bouchelouche, Pierre Bartels, Else Marie Bliddal, Henning Bendtzen, Klaus Stoltenberg, Michael |
author_facet | Eng, Grith Petersen Bouchelouche, Pierre Bartels, Else Marie Bliddal, Henning Bendtzen, Klaus Stoltenberg, Michael |
author_sort | Eng, Grith Petersen |
collection | PubMed |
description | OBJECTIVES: With the present study we wanted to explore the impact of treatment with a tumor necrosis factor-α -inhibitor (TNFi) on levels of soluble biomarkers in rheumatoid arthritis (RA) patients and to identify predictors of impaired drug levels and development of anti-TNFi antibodies (anti-TNFi Abs). METHODS: Blood samples from 26 patients with established RA were taken at baseline and following 6 months of treatment with adalimumab or infliximab. Samples were analyzed for levels of TNFi, interleukin (IL)-6, and soluble TNF-receptors 1 and -2 (sTNF-R1 and -2) and for presence of anti-TNFi Abs. Clinical and demographic data were recorded as well. RESULTS: During the initial 6 months treatment, DAS28(CRP) (Disease activity score in 28 joints using C-reactive protein) and levels of IL-6 and sTNF-R2 decreased significantly in patients without anti-TNFi Abs and in patients retaining detectable drug levels. The levels of other tested cytokines (TNF-α, TNF-β, IL-1ra, IL-1b, IL-8, IL-10, IL-12(p70), IL-13, IL-17A, IL-17F, and IL-33) were generally below detection limits. Higher baseline levels of IL-6 associated with undetectable levels of TNFi at follow-up. Anti-TNFi Abs were associated with decreased drug levels, but no predictors for anti-TNFi Ab development could be found. CONCLUSION: The effect of treatment with TNFi on RA disease activity depends on levels of active drug, and by presence of anti-TNFi Abs. In patients who retain detectable drug levels, and in the absence of anti-TNFi Abs, clinical outcome is improved during treatment, and circulating levels of IL-6 and sTNF-R2 decrease. Baseline levels of IL-6 may predict depletion of TNFi and may identify patients at risk of treatment failure. |
format | Online Article Text |
id | pubmed-5016088 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-50160882016-09-27 Anti-Drug Antibodies, Drug Levels, Interleukin-6 and Soluble TNF Receptors in Rheumatoid Arthritis Patients during the First 6 Months of Treatment with Adalimumab or Infliximab: A Descriptive Cohort Study Eng, Grith Petersen Bouchelouche, Pierre Bartels, Else Marie Bliddal, Henning Bendtzen, Klaus Stoltenberg, Michael PLoS One Research Article OBJECTIVES: With the present study we wanted to explore the impact of treatment with a tumor necrosis factor-α -inhibitor (TNFi) on levels of soluble biomarkers in rheumatoid arthritis (RA) patients and to identify predictors of impaired drug levels and development of anti-TNFi antibodies (anti-TNFi Abs). METHODS: Blood samples from 26 patients with established RA were taken at baseline and following 6 months of treatment with adalimumab or infliximab. Samples were analyzed for levels of TNFi, interleukin (IL)-6, and soluble TNF-receptors 1 and -2 (sTNF-R1 and -2) and for presence of anti-TNFi Abs. Clinical and demographic data were recorded as well. RESULTS: During the initial 6 months treatment, DAS28(CRP) (Disease activity score in 28 joints using C-reactive protein) and levels of IL-6 and sTNF-R2 decreased significantly in patients without anti-TNFi Abs and in patients retaining detectable drug levels. The levels of other tested cytokines (TNF-α, TNF-β, IL-1ra, IL-1b, IL-8, IL-10, IL-12(p70), IL-13, IL-17A, IL-17F, and IL-33) were generally below detection limits. Higher baseline levels of IL-6 associated with undetectable levels of TNFi at follow-up. Anti-TNFi Abs were associated with decreased drug levels, but no predictors for anti-TNFi Ab development could be found. CONCLUSION: The effect of treatment with TNFi on RA disease activity depends on levels of active drug, and by presence of anti-TNFi Abs. In patients who retain detectable drug levels, and in the absence of anti-TNFi Abs, clinical outcome is improved during treatment, and circulating levels of IL-6 and sTNF-R2 decrease. Baseline levels of IL-6 may predict depletion of TNFi and may identify patients at risk of treatment failure. Public Library of Science 2016-09-08 /pmc/articles/PMC5016088/ /pubmed/27606615 http://dx.doi.org/10.1371/journal.pone.0162316 Text en © 2016 Eng et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article Eng, Grith Petersen Bouchelouche, Pierre Bartels, Else Marie Bliddal, Henning Bendtzen, Klaus Stoltenberg, Michael Anti-Drug Antibodies, Drug Levels, Interleukin-6 and Soluble TNF Receptors in Rheumatoid Arthritis Patients during the First 6 Months of Treatment with Adalimumab or Infliximab: A Descriptive Cohort Study |
title | Anti-Drug Antibodies, Drug Levels, Interleukin-6 and Soluble TNF Receptors in Rheumatoid Arthritis Patients during the First 6 Months of Treatment with Adalimumab or Infliximab: A Descriptive Cohort Study |
title_full | Anti-Drug Antibodies, Drug Levels, Interleukin-6 and Soluble TNF Receptors in Rheumatoid Arthritis Patients during the First 6 Months of Treatment with Adalimumab or Infliximab: A Descriptive Cohort Study |
title_fullStr | Anti-Drug Antibodies, Drug Levels, Interleukin-6 and Soluble TNF Receptors in Rheumatoid Arthritis Patients during the First 6 Months of Treatment with Adalimumab or Infliximab: A Descriptive Cohort Study |
title_full_unstemmed | Anti-Drug Antibodies, Drug Levels, Interleukin-6 and Soluble TNF Receptors in Rheumatoid Arthritis Patients during the First 6 Months of Treatment with Adalimumab or Infliximab: A Descriptive Cohort Study |
title_short | Anti-Drug Antibodies, Drug Levels, Interleukin-6 and Soluble TNF Receptors in Rheumatoid Arthritis Patients during the First 6 Months of Treatment with Adalimumab or Infliximab: A Descriptive Cohort Study |
title_sort | anti-drug antibodies, drug levels, interleukin-6 and soluble tnf receptors in rheumatoid arthritis patients during the first 6 months of treatment with adalimumab or infliximab: a descriptive cohort study |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5016088/ https://www.ncbi.nlm.nih.gov/pubmed/27606615 http://dx.doi.org/10.1371/journal.pone.0162316 |
work_keys_str_mv | AT enggrithpetersen antidrugantibodiesdruglevelsinterleukin6andsolubletnfreceptorsinrheumatoidarthritispatientsduringthefirst6monthsoftreatmentwithadalimumaborinfliximabadescriptivecohortstudy AT bouchelouchepierre antidrugantibodiesdruglevelsinterleukin6andsolubletnfreceptorsinrheumatoidarthritispatientsduringthefirst6monthsoftreatmentwithadalimumaborinfliximabadescriptivecohortstudy AT bartelselsemarie antidrugantibodiesdruglevelsinterleukin6andsolubletnfreceptorsinrheumatoidarthritispatientsduringthefirst6monthsoftreatmentwithadalimumaborinfliximabadescriptivecohortstudy AT bliddalhenning antidrugantibodiesdruglevelsinterleukin6andsolubletnfreceptorsinrheumatoidarthritispatientsduringthefirst6monthsoftreatmentwithadalimumaborinfliximabadescriptivecohortstudy AT bendtzenklaus antidrugantibodiesdruglevelsinterleukin6andsolubletnfreceptorsinrheumatoidarthritispatientsduringthefirst6monthsoftreatmentwithadalimumaborinfliximabadescriptivecohortstudy AT stoltenbergmichael antidrugantibodiesdruglevelsinterleukin6andsolubletnfreceptorsinrheumatoidarthritispatientsduringthefirst6monthsoftreatmentwithadalimumaborinfliximabadescriptivecohortstudy |